Drugs / IMSAPEPIMUT

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT03562871 Aug 2018 → Feb 2021 non-small cell lung carcinoma IO Biotech Completed No outcome recorded
Phase 24 trials
Phase 2 NCT05280314 Dec 2023 → Apr 2025 overdue head and neck squamous cell carcinoma, melanoma IO Biotech Recruiting No outcome recorded
Phase 2 NCT05912244 Jun 2023 → Jun 2027 expected melanoma Memorial Sloan Kettering Cancer Center Active not recruiting No outcome recorded
Phase 2 NCT05077709 Apr 2022 → Nov 2025 head and neck squamous cell carcinoma, non-small cell lung carcinoma, urothelial carcinoma IO Biotech Completed No outcome recorded
Phase 2 NCT04445064 Aug 2020 → Jun 2024 hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma Cliniques universitaires Saint-Luc- Université Catholique de Louvain Terminated No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as IMSAPEPIMUT ChEMBL registry synonym — accepted as the source's own label CHEMBL6068401
Known as IO102 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03562871
4

NCT04445064

NCT05912244

NCT05077709

NCT05280314

Action Activate “Activation of IDO or PD-L1 specific T-cells through vaccination with the IDO and PD-L1 peptides (IO102-IO103) will boost natural killing of cancer cells and counteract immune...” NCT05077709
Modality Peptide “Activation of IDO or PD-L1 specific T-cells through vaccination with the IDO and PD-L1 peptides (IO102-IO103) will boost natural killing of cancer cells and counteract immune...” NCT05077709
Route Subcutaneous “administered subcutaneously (SC)” NCT03562871